Markers of primary mineralization are correlated with bone-bonding ability of titanium or stainless steel in vivo.
Critical events in the adaptation of osseous tissues to implant materials involve initial calcification of the newly synthesized bone. Previous studies indicated that bone-bonding but not nonbonding glass ceramics increase the matrix vesicle number, thereby compensating for delayed maturation of the extracellular organelles. The present study assessed whether this was also true for metal implants commonly used in orthopaedics and oral medicine. Bone-bonding titanium (Ti) or nonbonding stainless steel (SS) implants were placed in the right tibias of Sabra rats following ablation of the marrow. At 3, 6, 14, and 21 days postinjury, newly formed endosteal bone in the treated and contralateral limbs was removed and matrix vesicle-enriched membranes isolated. Alkaline phosphatase and phospholipase A2 specific activities and phosphatidylserine (PS) content were determined and compared with those of a nonsurgical control group. Results show that matrix vesicle alkaline phosphatase and phospholipase A2 activity and PS content was increased in the Ti-implanted limbs at 6 (peak), 14, and 21 days, although at levels less than observed in normal healing. Alkaline phosphatase activity remained elevated throughout the healing period. In contrast, these parameters were markedly inhibited in the SS-implanted limbs with respect to Ti or to normal healing. Both implants altered the systemic response associated with marrow ablation, but in an implant-specific manner. The results support the hypothesis that cells adjacent to bone-bonding materials can compensate for negative effects on primary mineralization during osteogenesis, whereas cells adjacent to nonbonding materials either do not compensate or are further depressed. The data support the use of the rat marrow ablation model as a tool for rapid, initial assessment of biomaterials in bone.
Braun
G
G
Willford Hall Medical Center, Lackland Air Force Base, Texas, USA.
Kohavi
D
D
Amir
D
D
Luna
M
M
Caloss
R
R
Sela
J
J
Dean
D D
DD
Boyan
B D
BD
Schwartz
Z
Z
D000469:Alkaline Phosphatase / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001853:Bone Marrow / Q000601:surgery; D001857:Bone Matrix / Q000166:cytology / Q000378:metabolism*; D002113:Calcification, Physiologic / Q000187:drug effects* / Q000502:physiology; D008297:Male; D008422:Materials Testing / Q000379:methods; D008566:Membranes / Q000201:enzymology; D008855:Microscopy, Electron, Scanning; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism; D016348:Osseointegration / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D010718:Phosphatidylserines / Q000378:metabolism; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D019736:Prostheses and Implants; D051381:Rats; D011919:Rats, Inbred Strains; D013193:Stainless Steel / Q000494:pharmacology*; D018709:Statistics, Nonparametric; D013977:Tibia / Q000502:physiology; D014025:Titanium / Q000494:pharmacology*; D014945:Wound Healing / Q000502:physiology
D010718:Phosphatidylserines; D013193:Stainless Steel; D014025:Titanium; D009247:NADH, NADPH Oxidoreductases; C028796:iodophenyl-nitrophenyl-phenyltetrazolium reductase; D010741:Phospholipases A; D054467:Phospholipases A2; D000469:Alkaline Phosphatase